港股異動丨啟明醫療-B(2500.HK)漲6.45% 低折價配股淨籌14.27億港元
格隆匯1月22日丨啟明醫療-B(2500.HK)漲6.45%,報87.5港元,高見89.3港元創近3個月新高,總市值370億港元。

啟明醫療今早公佈,以每股80.08港元配售合共1804.25萬股新H股,所得總額14.45億港元,涉股份佔擴大後已發行H股總數及已發行股份總數約4.18%及4.09%。配股價較昨日收市價82.2港元折讓2.58%。配售所得淨額14.27億港元,擬用於加速在研產品的開發及研究;其他新技術的開發和投資;以及作運營資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.